For research use only. Not for therapeutic Use.
Tenapanor HCl（Cat No.:I009752）is an oral medication approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. It functions by inhibiting the sodium/hydrogen exchanger 3 (NHE3) on the surface of intestinal epithelial cells. This inhibition reduces sodium absorption and increases water secretion into the intestinal lumen, which softens stools and accelerates gastrointestinal transit. Taken twice daily before meals, Tenapanor offers a novel approach to relieving constipation and abdominal symptoms associated with IBS-C. Its localized action in the gut minimizes systemic exposure, potentially reducing the risk of systemic side effects common with other treatments.
| Catalog Number | I009752 |
| CAS Number | 1234365-97-9 (2HCl) |
| Synonyms | AZD-1722; AZD 1722; AZD1722; RDX 5791; RDX-5791; RDX5791; Tenapanor; Tenapanor hydrochloride; Tenapanor dihydrochloride;3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoli |
| Molecular Formula | C50H68Cl6N8O10S2 |
| Purity | 98% |
| Target | Na+/H+ Exchanger (NHE) |
| Target Protein | P48764 |
| Solubility | Soluble in DMSO and water |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | 7.9 and 0.5 nM for rat and human NHE3 |
| IUPAC Name | 1-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea;dihydrochloride |
| InChI | InChI=1S/C50H66Cl4N8O10S2.2ClH/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-4 |
| InChIKey | VFRAXTZDILCRKY-OWRGXFNZSA-N |
| SMILES | O=S(C1=CC=CC([C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)=C1)(NCCOCCOCCNC(NCCCCNC(NCCOCCOCCNS(=O)(C4=CC=CC([C@@H]5CN(C)CC6=C5C=C(Cl)C=C6Cl)=C4)=O)=O)=O)=O.[H]Cl.[H]Cl |
| Reference | </br>1: Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study. Clin Pharmacol Drug Dev. 2017 Mar 24. doi: 10.1002/cpdd.341. [Epub ahead of print] PubMed PMID: 28339149.</br>2: Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacol Drug Dev. 2017 Mar 16. doi: 10.1002/cpdd.346. [Epub ahead of print] PubMed PMID: 28301096. |
